GleamWall
中文EN

INSM INSMED Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1104506 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY240.0%
TTM net income YoY48.8%
TTM EPS YoY54.6%
Revenue 3-yr CAGR75.6%
Net income 3-yr CAGR—

Margins

Gross margin84.4%
Operating margin-37.1%
Net margin-39.9%
FCF margin-41.3%
EBITDA margin-36.3%

Returns

ROE-72.5%
ROA-26.4%
ROIC (approx.)-43.8%
Asset turnover0.66x

Leverage & solvency

Liabilities / assets67.4%
Debt / equity0.76x
Current ratio2.86x
Interest coverage-6.93x

Cash quality & payout

Operating cash flow / net income0.98x
Accruals ratio-0.4%
Payout ratio—
Capex / revenue2.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$524.43M$425.49M$305.96M$263.84M$142.34M$107.42M$92.82M$104.44M
Cost of revenue$78.22M$67.21M$47.42M$44.22M$29.36M$28.07M$21.28M$26.15M
Gross profit$446.21M$358.27M$258.54M$219.62M$112.98M$79.34M$71.55M$78.29M
R&D expense$269.96M$210.03M$209.49M$254.91M$186.41M$177.19M$152.58M$179.73M
SG&A expense$253.03M$247.47M$247.26M$212.48M$186.38M$154.76M$147.54M$142.51M
Operating income-$89.37M-$1.55M-$153.32M-$319.75M-$366.00M-$312.88M-$248.14M-$230.41M
Interest expense$20.41M$20.27M$20.08M$20.60M$20.38M$21.25M$21.57M$21.55M
Pretax income-$97.65M-$11.37M-$162.10M-$326.93M-$368.70M-$320.44M-$255.67M-$234.28M
Income tax$2.67M$1.87M$1.47M$1.55M$1.32M$1.24M$912,000$1.27M
Net income-$100.32M-$13.24M-$163.56M-$328.49M-$370.02M-$321.69M-$256.58M-$235.55M
EBITDA-$86.02M$1.63M-$150.39M-$316.12M-$363.55M-$310.39M-$246.26M-$228.94M
EPS (basic)-0.46-0.06-0.76—-1.75-1.70-1.42—
EPS (diluted)-0.46-0.06-0.76—-1.75-1.70-1.42—
Weighted avg. shares (diluted)218.79M217.35M215.47M—211.76M189.30M180.86M—
Balance sheet
Cash & equivalents$396.56M$544.76M$582.19M$510.44M$334.76M$1.28B$403.25M$555.03M
Short-term investments$750.06M$615.55M$641.33M$919.60M$1.35B$572.44M$796.20M$878.80M
Receivables$259.27M$215.32M$178.56M$140.86M$65.26M$55.03M$47.75M$52.01M
Inventory$163.95M$142.38M$132.91M$132.07M$120.97M$107.61M$100.71M$98.58M
Current assets$1.71B$1.63B$1.61B$1.79B$1.93B$2.08B$1.40B$1.62B
PP&E, net$108.34M$107.22M$102.85M$102.94M$89.67M$90.00M$88.36M$80.05M
Goodwill$136.11M$136.11M$136.11M$136.11M$136.11M$136.11M$136.11M$136.11M
Intangibles$138.44M$93.49M$95.57M$97.65M$84.59M$56.13M$57.39M$58.65M
Total assets$2.23B$2.10B$2.08B$2.26B$2.36B$2.48B$1.80B$2.03B
Current liabilities$596.58M$438.74M$361.01M$468.87M$417.21M$311.68M$239.23M$297.53M
Short-term debt$10.23M——$0————
Long-term debt$544.86M$543.51M$542.22M$540.96M$539.72M$538.51M$1.11B$1.10B
Total debt$555.09M$543.51M$542.22M$540.96M$539.72M$538.51M$1.11B$1.10B
Total liabilities$1.50B$1.35B$1.37B$1.53B$1.42B$1.23B$1.70B$1.74B
Shareholders' equity$726.21M$757.49M$704.85M$738.98M$945.57M$1.25B$99.16M$285.38M
Net debt$158.53M-$1.25M-$39.97M$30.52M$204.96M-$745.82M$701.82M$548.35M
Shares outstanding219.32M218.28M216.52M214.26M212.58M211.11M181.90M179.38M
Cash flow statement
Operating cash flow-$36.46M-$88.83M-$222.74M-$247.60M-$219.76M-$205.57M-$262.09M-$195.98M
Capital expenditure$5.62M$6.26M$3.48M$16.59M$2.42M$3.48M$10.07M$6.77M
Free cash flow-$42.09M-$95.09M-$226.22M-$264.19M-$222.18M-$209.05M-$272.16M-$202.75M
Investing cash flow-$135.65M$24.51M$265.52M$389.41M-$762.23M$227.84M$80.41M$131.76M
Financing cash flow$23.64M$27.18M$29.51M$33.86M$33.41M$857.81M$29.00M$159.31M
Depreciation & amortization$3.35M$3.18M$2.93M$3.62M$2.46M$2.48M$1.88M$1.48M
Stock-based compensation$41.22M$41.25M$45.75M$39.04M$31.43M$42.98M$39.26M$26.55M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.